Could one engineered tRNA address thousands of premature stop signals?
LinkedIn caption
🧬 Could one engineered tRNA address thousands of premature stop signals?
Brian Bodemann’s ARDD 2026 presentation described ARTAN Bio’s strategy for a recurring mutation: conversion of the CGA arginine codon into a premature stop. The official recap identifies roughly 68,000 susceptible sites across 16,000 genes. An engineered suppressor tRNA is designed to insert arginine at the resulting UGA signal, allowing production of a full-length protein.
💡 The early evidence spans delivery and protein restoration. Bodemann reported delivery to six tested mouse organs and restoration of full-length p53 in Calu-6 cells. A separate program in primary human hematopoietic stem cells is working toward IND-enabling studies for clonal hematopoiesis. The scientific appeal is addressing a shared mutation pattern across many genes; whether that produces safe, useful treatments still requires further preclinical and clinical testing.
#ARDD2026 #RNAtherapeutics #AgingBiology
X caption
🧬 Brian Bodemann brought ARTAN Bio’s suppressor-tRNA approach to #ARDD2026: restoring full-length proteins after premature stop mutations. Early-stage cell and mouse studies are guiding the next steps. These findings are preclinical; clinical relevance remains to be tested.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
